TAVI: 60 Second Insights
Published: 28 March 2018
-
Views:
5
-
Likes:
7
-
Views:
5
-
Likes:
7
-
Up Next -
Part 8 | Session 2 Francesco Maisano
-
Part 1 | Session 1 Nicolas Van Mieghem Nicolas M Van Mieghem
-
Part 1 | Session 2 Francesco Maisano Francesco Maisano
-
Part 2 | Session 1 Nicolas Van Mieghem Nicolas M Van Mieghem
-
Part 2 | Session 2 Francesco Maisano Francesco Maisano
-
Part 3 | Session 1 Nicolas Van Mieghem Nicolas M Van Mieghem
-
Part 3 | Session 2 Francesco Maisano Francesco Maisano
-
Part 4 | Session 1 Nicolas Van Mieghem Nicolas M Van Mieghem
-
Part 4 | Session 2 Francesco Maisano Francesco Maisano
-
Part 5 | Session 1 Nicolas Van Mieghem Nicolas M Van Mieghem
-
Part 5 | Session 2 Francesco Maisano Francesco Maisano
-
Part 6 | Session 1 Nicolas Van Mieghem Nicolas M Van Mieghem
-
Part 6 | Session 2 Francesco Maisano Francesco Maisano
-
Part 7 | Session 1 Nicolas Van Mieghem Nicolas M Van Mieghem
-
Part 7 | Session 2 Francesco Maisano Francesco Maisano
Overview
A short series of 60-second insight videos on TAVI.
More from this programme
Part 1
Do you think it is necessary to perform coronary revascularisation pre-TAVR? Do you use FFR/iFR decision-making?
| 2 sessions | |
| Nicolas Van Mieghem | Watch now |
| Francesco Maisano | Watch now |
Part 2
Are we ready to be doing TAVR in low risk patients?
| 2 sessions | |
| Nicolas Van Mieghem | Watch now |
| Francesco Maisano | Watch now |
Part 3
Which patients are you performing TAVR in now (High/Medium risk)?
| 2 sessions | |
| Nicolas Van Mieghem | Watch now |
| Francesco Maisano | Watch now |
Part 4
Which is your preferred valve, and why?
| 2 sessions | |
| Nicolas Van Mieghem | Watch now |
| Francesco Maisano | Watch now |
Part 5
How would you recommend someone start a TAVR program?
| 2 sessions | |
| Nicolas Van Mieghem | Watch now |
| Francesco Maisano | Watch now |
Part 6
What is the most important clinical trial data and why?
| 2 sessions | |
| Nicolas Van Mieghem | Watch now |
| Francesco Maisano | Watch now |
Part 7
What is the biggest innovation in TAVR over the past 12-24 months?
| 2 sessions | |
| Nicolas Van Mieghem | Watch now |
| Francesco Maisano | Watch now |
Part 8
What proportion of your patients have a TAVR rather than and surgical AVR?
| 2 sessions | |
| Nicolas Van Mieghem | Watch now |
| Francesco Maisano | Watch now |
Faculty Biographies
Nicolas M Van Mieghem
Medical Director
Dr Nicolas M Van Mieghem obtained his medical degree and cardiology degree at the Catholic University of Leuven, Belgium. After subsequent fellowships in interventional cardiology in Ziekenhuis Oost-Limburg Genk, Belgium, Lenox Hill Hospital, New York, US and Erasmus Medical Center, Rotterdam, the Netherlands, he joined the department of interventional cardiology at the Thoraxcenter, Erasmus Medical Center, as a senior staff member in February 2010.
He is involved in the percutaneous coronary interventions and structural heart program. He obtained the degree of PhD based upon his research in transcatheter valve therapies. So far he has published and co-authored approximately 130 scientific papers in peer-reviewed journals.
Dr Van Mieghem is principle investigator and steering committee member in multiple ongoing international trials evaluating various coronary and transcatheter valve technologies. He is a Fellow of the European Society of Cardiology and is currently…